Recombinant human interferon α2b for injection (Pseudomonas)

1. Pharmacokinetics The average serum concentration of Anfulong is the same after intramuscular and subcutaneous injections. The highest serum concentration is approximately 1.2-33.6 units/ml and occurs 1 to 24 hours later. The elimination half-life of Anfulong after intramuscular or subcutaneous injection is 4-12 hours, and its maximum blood concentration occurs 3.5-8 hours after administration. 2. Clinical studies Interferon alpha; 2b can make hepatitis B e antigen negative, normalize transaminase levels, reduce liver inflammation, and delay the progression to cirrhosis and improve the quality of life in 20%-30% of patients. Studies have shown that interferon alpha; 2b can normalize serum ALT, improve liver tissue and reduce the amount of virus in patients with chronic hepatitis C. Some other studies have also shown that interferon alpha; 2b has clinical significance in tumor regression or hairy cell leukemia disease stabilization, and has clinical significance in the treatment of patients with AIDS-related Kaposi's sarcoma. Interferon alpha 2b is also very important for patients with chronic myeloid leukemia, and can also be used as an adjunct to intermittent treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recombinant human interferon α2b

This product is a yellowish or white loose body. After dissolving, it becomes a clear liquid with no insoluble matter visible to the naked eye.

Anfulong can be used to treat the following viral diseases and tumors: chronic hepatitis B and C, herpes zoster, genital warts, multiple myeloma, hairy cell leukemia, chronic myeloid leukemia, renal cell carcinoma, AIDS-related Kaposi's sarcoma, lymphoma, malignant melanoma, etc.

This product can be injected intramuscularly, subcutaneously and intralesionally. 1. Chronic hepatitis B: The recommended dose is 3 to 5 million international units each time, injected once a day or every other day, and a course of treatment of 3 to 6 months. The doctor can adjust the dose according to the specific situation of the patient. 2. Chronic hepatitis C: The recommended dose is 3 to 5 million international units each time, injected once a day or every other day, and a course of treatment of 3 to 6 months. The doctor can adjust the dose according to the specific situation of the patient. 3. Genital warts: The recommended dose is 1 to 3 million international units each time, injected three times every other day, and a course of treatment of 1-2 months. 4. Hairy cell leukemia: The recommended dose is 3 million international units each time, injected three times every other day, and the doctor can adjust the dose according to the specific situation of the patient. Usually, the effect is shown after 1 to 2 months of treatment, and intermittent treatment can be carried out afterwards to achieve long-term remission of the disease. 5. Chronic myeloid leukemia: The recommended dose is 3 million to 9 million international units per day for three months of treatment. The doctor can adjust the dose according to the specific situation of the patient. After the blood picture is relieved, maintenance treatment can be carried out, with injection every other day. Cytogenetic indicators can be relieved after 9 to 10 months. 6. Lymphoma (cystic): The recommended dose is 3 million international units, injected three times every other day per week. According to the tolerance of different patients, the dose can be increased weekly to the maximum tolerated dose (9 million to 18 million international units), injected three times every other day per week, and a course of treatment of 8 to 12 weeks. If there is no exacerbation of the disease or severe intolerance reaction, this dose should be continued for at least 12 months. The doctor can adjust the dose according to the specific situation of the patient, and photochemotherapy can improve the efficacy. 7. AIDS-related Kaposi's sarcoma: The recommended dose is 18 million international units per day. If possible, the dose can be gradually increased to 36 million international units. If there is no exacerbation of the disease or severe intolerance reaction, this therapy should be maintained continuously. When the response is stable, the dose is changed to 18 million IU each time, injected three times every other day a week. 8. Malignant melanoma: The recommended dose is 9 to 18 million IU each time, injected three times every other day a week until the effect is seen, and then continued treatment, 18 million IU each time, injected three times every other day a week. The doctor can adjust the dose according to the patient's specific situation. After surgical resection of stage I and II malignant melanoma, the use of this product for adjuvant treatment can reduce the recurrence rate.

1. Common adverse reactions to this product include cold-like symptoms, such as fever, headache, chills, fatigue, muscle aches, joint pain, etc. Some patients may experience anorexia, nausea, diarrhea, vomiting, leukopenia, thrombocytopenia, and increased transaminase, which can return to normal after stopping the drug. Occasionally, there are insomnia, rash, hair loss, increased or decreased blood pressure, tinnitus, decreased vision, and nervous system dysfunction. 2. Adverse reactions are mostly transient and reversible reactions, which often occur in the first week of medication. Adverse reactions usually disappear 48 hours after injection. If moderate to severe adverse reactions occur, consider adjusting the patient's medication dosage or stopping the medication. If an allergic reaction occurs, the medication should be stopped immediately.

This product is contraindicated for patients with a history of allergy to any component of the preparation. It is also contraindicated for patients with severe heart disease, autoimmune disease, epilepsy, central nervous system damage, severe liver, kidney or bone marrow dysfunction, and other serious diseases who cannot tolerate this product.

Precautions for children: There is still limited experience in the use of this drug in children. For such cases, the drug should be used in accordance with the doctor's instructions after carefully weighing the pros and cons. Precautions for pregnancy and lactation: 1. Precautions for pregnant women are limited, and the safe use of this product during pregnancy has not yet been established. Therefore, when the condition of a pregnant woman seriously requires the use of this product, it should be carefully considered by the clinician, and it can only be used when the benefits of the drug to the mother outweigh the potential risks to the fetus. 2. There is no data showing whether interferon is secreted through breast milk after the use of this product. When breastfeeding women need to use the drug, they should consider the importance of this product to the mother to decide whether to terminate breastfeeding or stop using the drug. Precautions for the elderly: 1. For elderly patients with heart disease and advanced cancer, an electrocardiogram should be performed before and during treatment with this agent, and the dose should be adjusted or the use of this product should be stopped according to the doctor's instructions. 2. It is packaged in a controlled glass bottle or prefilled glass syringe, 1 ml each.

Interferon may change the activity of some enzymes, especially reduce the activity of cytochrome P450, thus affecting the metabolism of drugs such as cimetidine, warfarin, theophylline, diazepam, and propranolol. When used in combination with drugs with central effects, interactions may occur.

Store at 2-8℃ away from light.

5 million international units per bottle

2 years

Tianjin Sinobioway Biomedicine Co., Ltd.

• Founded in:

  1992-10-27

• Address:

  No. 203, Huanghai Road, Tianjin Economic and Technological Development Zone

• Tax NO.:

  91120116600600595N

• Registered Funds:

  228.23410473 yuan

• Website:

  Log in to view

• Email:

  Log in to view